Vraylar (cariprazine) costs roughly $1,900 per month at retail price without insurance, making it one of the more expensive atypical antipsychotics on the market. There are several real ways to bring that cost down significantly, and in some cases to zero, depending on your insurance status and income.
Current Retail Prices
A 30-day supply of Vraylar runs between $1,879 and $1,938 at full retail price, regardless of dose. Pharmacy discount coupons through platforms like GoodRx can reduce that to roughly $1,400 to $1,600, but that’s still a steep monthly expense for most people. The savings from these coupons alone won’t make Vraylar affordable if you’re paying entirely out of pocket.
AbbVie’s Patient Assistance Program
The most impactful option for many people is myAbbVie Assist, the manufacturer’s patient assistance program. If you qualify, you can receive Vraylar at no cost. The program is available if you’re uninsured or have limited insurance coverage (including Medicare) and meet the income guidelines.
AbbVie’s income thresholds are relatively generous, reaching up to 600% of the federal poverty level:
- 1-person household: $63,840 or less per year
- 2-person household: $86,560 or less
- 3-person household: $109,280 or less
- 4-person household: $132,000 or less
For households larger than four, add $22,720 for each additional dependent. If you have insurance but still face high out-of-pocket costs, AbbVie may evaluate your application based on a combination of your coverage, income, and medical expenses. Your prescribing doctor’s office typically helps submit the application, so ask them about it directly.
Getting Insurance to Cover More
Most insurers place Vraylar on a higher formulary tier because no generic version is currently available. That means higher copays or coinsurance for you. But the bigger hurdle is that many plans require prior authorization and step therapy before they’ll cover it at all.
Step therapy means your insurer wants documentation that you tried and failed (or couldn’t tolerate) at least one generic atypical antipsychotic before approving Vraylar. Aetna’s policy is a typical example: they require evidence of an inadequate response or intolerance to one generic option. If your doctor has already tried other medications with you, make sure that history is clearly documented in your medical records. Your doctor’s office handles the prior authorization paperwork, but you can speed things up by confirming they’ve submitted it and following up with your insurer if you haven’t heard back within a week or two.
If your prior authorization is denied, you have the right to appeal. Ask your doctor to write a letter of medical necessity explaining why Vraylar is specifically needed in your case. Many denials get overturned on appeal, particularly when there’s a documented history of failed alternatives.
Medicare and Extra Help
If you’re on Medicare, Vraylar is covered under Part D prescription drug plans, though it typically sits on a higher cost tier. Your out-of-pocket share can still be substantial. One way to reduce it is through Medicare’s Extra Help program (also called the Low-Income Subsidy), which helps cover premiums, deductibles, and copays for people with limited income and resources. If you qualify, your copay for a high-tier drug like Vraylar drops dramatically.
You can apply for Extra Help through the Social Security Administration’s website or by calling 1-800-772-1213. Even if you’re not sure you qualify, it’s worth applying since the financial thresholds are higher than many people expect. You may also be eligible for myAbbVie Assist alongside Medicare if your out-of-pocket costs remain high.
Generic Cariprazine: What to Expect
The FDA approved a generic version of cariprazine (made by Zydus Pharmaceuticals) back in September 2022. However, the brand-name patents on Vraylar don’t expire until late 2028 and 2029, which means the generic can’t launch until those protections end. Zydus holds 180-day exclusivity as the first generic applicant, so it will likely be the only generic option for six months after launch before other manufacturers enter the market.
Realistically, you can expect generic cariprazine to become available around late 2029, unless a settlement or legal development moves that date earlier. When generics do arrive, prices typically drop by 80% or more within a couple of years, which would bring a monthly supply closer to $200 to $400. That’s still a few years away, so the strategies above are your best options in the meantime.
Lower-Cost Alternatives Worth Discussing
If none of the savings options bring Vraylar within reach, it’s worth talking to your doctor about whether a generic atypical antipsychotic could work for you. Several are available at a fraction of the cost. Risperidone, olanzapine, and generic aripiprazole (the active ingredient in Abilify) all treat schizophrenia and bipolar disorder and are available as generics for $10 to $50 per month at many pharmacies.
These medications aren’t identical to Vraylar. They work on slightly different receptor pathways and have different side effect profiles. Some cause more weight gain or sedation than Vraylar, which is part of why many doctors prefer cariprazine for certain patients. But if cost is the barrier between taking medication and not taking it, a well-tolerated generic alternative is far better than going without treatment. Your doctor can help weigh the tradeoffs based on your specific diagnosis and treatment history.